Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
about
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Psoriasis patients with psoria ...... hase 3 studies of secukinumab.
@en
type
label
Psoriasis patients with psoria ...... hase 3 studies of secukinumab.
@en
prefLabel
Psoriasis patients with psoria ...... hase 3 studies of secukinumab.
@en
P2093
P2860
P1476
Psoriasis patients with psoria ...... phase 3 studies of secukinumab
@en
P2093
Ari Gnanasakthy
Bintu Sherif
Boni E Elewski
Bruce E Strober
Charis Papavassilis
Isabelle Gilloteau
Margaret Mordin
P2860
P304
P356
10.1080/09546634.2017.1294727
P50
P577
2017-03-07T00:00:00Z